Detailed instructions for selumetinib: usage, dosage, contraindications and precautions

Selumetinib is a MEK inhibitor that is mainly used to treat certain types of tumors, especially advanced or metastatic, unresectable low-grade glioblastoma and some neurofibromas. As a targeted drug, selumetinib inhibits the intracellular MAPK signaling pathway by inhibiting MEK (mitogen-activated protein kinase), thereby slowing down the proliferation of tumor cells and delaying the development of tumors. The following is a detailed description of the usage, dosage, contraindications and precautions of selumetinib.

1.Usage and dosage

Dosage for adult patients

The usual dosage of selumetinib is 50mg twice daily, and continuous treatment is usually required. During treatment, the dose should be adjusted according to the patient's tolerance. If obvious adverse reactions occur, the dose can be reduced according to the doctor's advice.

Selumetinib should be taken orally, preferably with food, to reduce gastrointestinal discomfort and increase the bioavailability of the drug. It should be taken at the same time every day to ensure a stable concentration of the drug in the body.

Dosage for Pediatric Patients

For children 6 years old and above, the dose of selumetinib is usually 25mg twice daily. The specific dose needs to be adjusted according to body weight and individual conditions, and needs to be carried out under the guidance of a doctor. The safety and efficacy when used in children are still under study, so special attention needs to be paid to the adverse reactions and tolerability of the drug.

2.Dose adjustment

During treatment, if the patient experiences obvious adverse reactions (such as severe rash, gastrointestinal symptoms, heart problems, etc.), the doctor may adjust the dose based on the patient's symptoms and examination results. In some cases, it may be necessary to temporarily discontinue the drug or reduce the dose until the adverse effects resolve.

3.Contraindications

Although selumetinib is an effective targeted drug, it also has some contraindications. Selumetinib should be avoided in the following patients:

Patients who are allergic to selumetinib or other MEK inhibitors, including patients who experience severe allergic reactions (such as urticaria, dyspnea, etc.), should not use this drug.

Pregnant and lactating women: Selumetinib may cause potential harm to the fetus and infant, so this drug is contraindicated in pregnant women and lactating women should also avoid its use. During treatment, female patients should use effective contraception to prevent pregnancy.

Patients with severe hepatic impairment: Selumetinib is mainly metabolized by the liver. Patients with severe hepatic impairment may not be able to metabolize the drug normally, increasing the risk of toxicity. Therefore, patients with poor hepatic function should avoid the use of selumetinib or need to use it with caution under the supervision of a physician.

4.Notes

Heart problems: Selumetinib can cause cardiac toxicities such asQT prolongation and irregular heartbeats. During treatment, patients need to have their electrocardiograms checked regularly, especially those with a history of or high risk for heart disease. If severe heart discomfort or electrolyte abnormalities occur, your doctor may withhold or adjust your medication.

Adverse Skin Reactions: Selumetinib may cause severe rash, erythema, peeling, and other skin reactions, especially early in treatment. These skin reactions may affect the patient's quality of life and may lead to discontinuation of treatment. If the skin reaction is severe, the patient should seek medical treatment in time, and the doctor will adjust the dosage or take other drug treatments according to the situation.

Gastrointestinal symptoms: Among the common side effects of selumetinib are nausea, vomiting, diarrhea, and abdominal pain, especially early in treatment. To reduce gastrointestinal discomfort, patients can choose to take medications after meals or take symptomatic medications as recommended by their doctor to relieve symptoms. If gastrointestinal discomfort is severe, your doctor may withhold treatment until symptoms resolve.

Eye problems: Selumetinib may cause eye symptoms such as dry eyes and blurred vision. During the treatment process, patients should check their eye conditions regularly and report to the doctor promptly if vision loss or eye discomfort occurs. The doctor will decide whether the treatment plan needs to be adjusted based on the specific situation.

Liver function monitoring: Selumetinib may cause increases in liver enzymes, so regular monitoring of liver function indicators is required, especially during the initial stages of treatment. If liver function abnormalities are evident, dosage adjustments or drug therapy may need to be suspended.

Selumetinib, as a targeted drug, has significant effects in treating certain types of tumors, but patients need to follow strict dosage, contraindications and precautions when using it. Patients should undergo regular heart, liver and eye examinations during treatment, and be aware of possible skin reactions and gastrointestinal discomfort caused by the drug. When using selumetinib, patients should strictly follow the doctor's instructions, adjust the dosage according to their own conditions, and report any discomfort symptoms in a timely manner to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.koselugo.com